Genetic defects in pyruvate dehydrogenase complex (PDC) cause lactic acidosis, neurological deficits, and often early death. Most mutations of PDC are localized in the K subunit of the pyruvate dehydrogenase (E1) component. We have kinetically characterized a patient's missense mutation KH44R in E1K by creating and purifying three recombinant human E1s (KH44R, KH44Q, and KH44A). Substitutions at histidine-15 resulted in decreased V max values (6% KH44R ; 30% KH44Q ; 90% KH44A) while increasing K m values for thiamine pyrophosphate (TPP) compared to wild-type (KH44R, 3-fold; KH44Q, 7-fold ; KH44A, 10-fold). This suggests that the volume of the residue at site 15 is important for TPP binding and substitution by a residue with a longer side chain disrupts the active site more than the TPP binding site. The rates of phosphorylation and dephosphorylation of KH44R E1 by E1-kinase and phospho-E1 phosphatase, respectively, were similar to that of the wild-type E1 protein. These results provide a biochemical basis for altered E1 function in the KH44R E1 patient. ß
Introduction
Mammalian pyruvate dehydrogenase complex (PDC) is composed of multiple copies of several components, namely, pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3), an E3-binding protein (E3BP), and two regulatory components, E1-kinase (PDK) and phospho-E1 phosphatase (PDP) [1^4] . PDC catalyzes the oxidative decarboxylation of pyruvate, using CoASH and NAD , to acetyl-CoA with the concomitant formation of CO 2 and NADH [1, 4] . E1, an K 2 L 2 heterotetramer, catalyzes the rate-limiting step in the PDC reaction [5] . E1 activity consists of two partial reactions: (i) the decarboxylation of pyruvate and (ii) the reductive acetylation of lipoyl moieties covalently linked to E2.
PDC is controlled post-translationally by phosphorylation (inactivation) and dephosphorylation (reactivation) of the E1 component by several isoforms of PDK and PDP, respectively [6^8] . E1 can be phosphorylated by PDK on three serine residues, serine 293 (site 1), serine 300 (site 2) and serine 232 (site 3), on each of its K subunits. Phosphorylation of any one site on either K subunit is enough for complete inactivation of the E1 component (and hence PDC) [9, 10] . It has been shown previously that the phosphorylation rates of the serine residues are sitespeci¢c [9, 10] ; however, the order of dephosphorylation is random [10, 11] .
Since PDC controls the oxidation of pyruvate derived from carbohydrates and some amino acids, PDC de¢ciency limits the oxidation of carbohydrates in the organism. A majority of patients displaying PDC de¢ciency have been found to have a de¢ciency in the E1 component. Of these 130 patients, approximately 70 have been shown to have point mutations in E1, all in the K subunit [12] . The remaining 60 patients were found to have either insertion or deletion mutations [12] . E1 de¢ciency is an X-linked disorder. Mutation in males results in severe lactic acidosis and varied neurological dysfunctions, while in females (depending on X-chromosome inactivation) there is little increase in blood lactate but neurological defects and structural abnormalities are much more severe [13] . Since glucose is the major source of energy in the brain, there is a lack of energy production and thus dysfunction in the brain. A rationale therapy for these mutations is to limit the amount of carbohydrate intake and increase the amount of fat consumed [14, 15] . Another strategy is to give the patient high doses of thiamine [161 8] . Several patients, reported thus far, have shown improvement by pharmacological doses of thiamine [18^20]. One patient, who was thiamine responsive, was reported to have a histidine to arginine substitution at residue 15 in the E1K subunit [18] . Addition of high concentrations of thiamine pyrophosphate (TPP) to lymphoblastoid and ¢broblast extracts from this patient resulted in a marked increase in PDC activity in vitro. The activity of the patient's PDC was extremely low at 0.1 WM TPP while at 400 WM TPP, the activity was approximately 35% of normal controls (K m for TPP of control ¢broblasts is about 0.07 WM) [18] . An immunoblot analysis using anti-E1 antibodies showed control levels of the individual subunits [18] . This suggested that the patient's enzyme was catalytically less active. The aim of this study was to elucidate the involvement of histidine-15 in E1K on the human E1 catalysis and regulation.
Materials and methods

Plasmid constructs
The recombinant expression vector pQE-9:E1K/L was engineered previously in this laboratory [21] . Plasmids were puri¢ed using a Wizard Plus MiniPreps DNA Puri¢cation System (Promega). The primers used for site-directed mutagenesis were synthesized by the CAMBI Nucleic Acid Facility at this university (Table 1) . Site-directed mutagenesis was done using a two-step polymerase chain reaction (PCR) protocol for the engineering of the KH44R and KH44Q mutant E1K inserts [22] . These Bam-HI-digested inserts were ligated into BamHI-digested, 5P-dephosphorylated pQE-9 vectors to form the expression vectors pQE-9:H44R E1K and pQE-9:H44Q E1K. The pQE-9:H44A E1K vector was created using a QuickChange Site-directed Mutagenesis kit (Stratagene). The E1K inserts (V1.1 kb) of the mutant pQE-9 expression vectors were sequenced utilizing the dideoxy termination method using Sequenase. Mutant constructs with the correct sequence were digested with PvuI and SalI simultaneously and the resulting 1.85 kb fragment was puri¢ed using a QiaexII Gel Extraction kit (Qiagen). A 3.8 kb pQE-3:E1L wild-type fragment digested with XhoI and PvuI was then ligated to this 1.85 kb fragment. The resulting ligations formed the vectors pQE-9:H44R E1K/L, pQE-9:H44Q E1K/L, and pQE-9:H44A E1K/L. The ligation mixtures were transformed into an Escherichia coli M15 CaCl 2 competent cell line containing pDM1.1, which encodes the lac repressor. The 5P end, the site of mutation, and the 3P end of the E1K/L coexpression vectors were then resequenced as above.
Overexpression of recombinant proteins
The wild-type and mutant E1 proteins encoded by these plasmids were overexpressed and puri¢ed by a slight modi¢cation of the procedure described previously [21] . The modi¢cations included the addition of 5% glycerol to all of the bu¡ers and 50 mM imidazole to the wash bu¡er. E1 was concentrated either by 60% ammonium sulfate precipitation or by using a Ultrafree-15 Centrifugal Filter Device (50 kDa molecular mass cuto¡) (Millipore). A coexpression vec-tor containing the cDNAs encoding the human E2 component and the E3BP was a gift from Dr. Robert A. Harris [23] . E2^E3BP subcomplex was overexpressed and puri¢ed by the method of Yang et al. [24, 25] . The E2^E3BP subcomplex was s 90% pure and had no detectable E. coli PDC or K-ketoglutarate dehydrogenase complex activities. Recombinant human E3 protein was overexpressed and puri¢ed using a vector not yet published (Y. Hong, M.S. Patel, unpublished construct) by methods reported previously [26] .
BL21(DE3) E. coli cell lines harboring either expression vectors containing the cDNA for rat PDK1 or PDK2 were generous gifts from Dr. R.A. Harris. Overexpression and puri¢cation of PDK1 and PDK2 were done as previously published [25, 27] . Aliquots were stored at 380³C in 50% glycerol. A pET-28a vector containing the cDNA for rat PDP1 was a generous gift from Dr. R.A. Harris. This vector was transformed into CaCl 2 competent BL21(DE3) E. coli cells, containing pGroESL, a vector encoding the chaperonins GroES and GroEL, a gift from Dr. Anthony A. Gatenby (DuPont). PDP1 was puri¢ed as described by Huang et al. [28] . The fractions containing PDP1 were pooled, concentrated and glycerol was added to a ¢nal concentration of 50%.
Purities of puri¢ed proteins were determined by densitometry of 12% sodium dodecyl sulfate (SDS)p olyacrylamide gels after Coomassie blue staining. Protein concentrations were measured by Bio-Rad protein assay using bovine serum albumin as standard.
Pyruvate dehydrogenase complex activity assay
Overall PDC activity was assayed by PDC reconstitution assay by measuring the formation of NADH [29] . For reconstitution of PDC, 1 or 2 Wg of E1 with an excess amount of both E2^E3BP (3 or 6 Wg) and E3 (3 or 6 Wg) was incubated in 50 mM potassium phosphate, pH 7.5. For measurement of PDC activity, reconstituted PDC was incubated with 2 mM MgCl 2 , 1.4 mM NAD , 4 mM cysteine, 156 WM CoASH, and TPP concentrations varying from 350 to 7500 WM in a 1-ml reaction volume. The reaction was started by the addition of pyruvate to a ¢nal concentration of 2 mM and the change in absorbance at 340 nm was measured. One unit of enzyme activity is equivalent to one Wmole NADH formed per minute. E1 activity was measured by the reduction of 2, 6-dichlorophenolindophenol (DCPIP) at 600 nm [25, 30] . The conditions for DCPIP assay were as follows: 50 mM potassium phosphate bu¡er (pH 7.0), 500 WM TPP, 10 mM MgCl 2 , and 100 WM DCPIP with 10^30 Wg E1; the reaction was started by the addition of pyruvate to 5 mM in a ¢nal volume of 1 ml.
E1 phosphorylation assay
Incorporation of 32 P from [ 32 P]ATP into E1 was measured as described previously [10] . E1 (10 Wg) was incubated in 20 mM potassium phosphate bu¡er (pH 7.0) containing 10 Wg E2^E3BP, 1 mM MgCl 2 , 0.1 mM EDTA, 2 mM dithiothreitol, 200 WM ATP (speci¢c radioactivity of 460^960 cpm/pmol ATP) with V10 ng of PDK1 or PDK2 at 30³C [10] . At various time intervals, aliquots were removed and placed on 10% trichloroacetate (TCA) presoaked ¢l-ter papers and dropped into a 10% TCA, 10 mM pyrophosphate solution. These ¢lter papers were washed, air-dried and the radioactivity associated was measured by a Beckman LS 6500 Multi-Purpose scintillation counter.
Site 3 was shown to be phosphorylated only by PDK1 and not PDK2 [31] . That allowed us to study phosphorylation of site 3 only. For site-speci¢c 32 Pphosphorylation of site 3, E1 protein was phosphorylated as mentioned above by PDK2 in the presence of the E2^E3BP subcomplex with 200 WM ATP (non-radioactive). After sites 1 and 2 were phosphorylated, 10 Wg PDK1 and [ 32 P]ATP (¢nal speci¢c radioactivity of 1460^1500 cpm/pmol ATP) were added and incorporation of [ 32 P]PO 4 was measured as mentioned above.
E1 dephosphorylation assay
Dephosphorylation of E1 was measured using a modi¢cation of Korotchkina and Patel [10] . Phosphorylation reactions (200 Wl), containing 20 Wg of wild-type or mutant E1 proteins, 0.06 Wg PDK1 or PDK2 and 200 WM [Q-32 P]ATP (speci¢c radioactivity of 1460^1500 cpm/pmol), were stopped by the depletion of ATP. This was accomplished by adding 4 Wg yeast hexokinase and 500 WM glucose to the reaction mixture and incubating for 15 min at 30³C. MgCl 2 and CaCl 2 were then added to ¢nal concentrations of 10 mM and 100 WM, respectively. Dephosphorylation was started by the addition of 1.5 Wg PDP1. At various time intervals, aliquots were removed and added to SDS-protein sample bu¡er, boiled for 1 min and stored at 320³C until they were separated on 10% SDS^polyacrylamide gels. Gels were dried and the amount of phosphorylated E1 was measured by densitometry by a BioRad phosphoimager.
Binding of E1 to the E2^E3BP subcomplex
Binding studies of E1 to the E2^E3BP subcomplex were carried out in order to determine whether the mutant E1 proteins were able to bind to the E2Ê 3BP subcomplex as well as the wild-type enzyme. The ¢rst approach consisted of measuring PDC speci¢c activity by PDC reconstitution assay with increasing amounts of E1 protein (0^2 Wg) and constant amounts of E2^E3BP subcomplex (1 Wg) and E3 (0.85 Wg). The data were plotted (1/speci¢c activity versus the ratio of E2^E3BP/E1 (Wg/Wg)) in Sigma Plot (Jandel Scienti¢c, CA). The x-intercept was taken as the minimum amount of E1 protein needed to fully activate 1 Wg of E2^E3BP subcomplex.
Using the second experimental approach E1s (100, 150 and 200 Wg) were incubated with E2^E3BP (100 Wg) for 30 min at room temperature in 120 Wl of 50 mM potassium phosphate bu¡er, pH 7.5. One hundred Wl of incubation mixture were subjected to gel¢ltration on Superdex 200 HR 10/30 (Amersham Pharmacia Biotech) to separate E1 bound to E2Ê 3BP and unbound E1. Two peaks were detected, i.e., E1^E2^E3BP and free E1. The integrated areas of the peaks were calculated by Unicorn 3.21 program. The amount of E1 bound to E2 was calculated by subtracting the integrated area of the peak of E2Ê 3BP in the absence of E1 from the integrated area of the peak of the subcomplex E1^E2^E3BP.
Thermostability of E1 proteins at 37³C
The thermostability of the wild-type and the mutant E1 proteins were measured in both the presence and absence of the E2^E3BP subcomplex. In the absence of the E2^E3BP subcomplex, E1 protein (2.1 WM) was incubated at 37³C in 50 mM potassium phosphate bu¡er (pH 7.0) with TPP concentration from 0 to 1 mM. In the presence of E2^E3BP subcomplex, E1 protein (0.
3BP), reconstituted with a total of 3 or 6 Wg of E2^E3BP and 3 or 6 Wg of E3, and PDC activity measured.
Results
Pyruvate dehydrogenase activity
Kinetic analysis showed that the substitution of Khistidine-44 by arginine, as found in the patient, caused a 94% reduction in the V max , while increasing the K m value for TPP by only 3-fold (Table 2) . Substitution of this histidine residue by a glutamine residue only caused a 69% reduction in V max , but a 7-fold increase in the K m value for TPP. Substitution of K-histidine-44 with an alanine residue had no signi¢cant e¡ect on the mutant enzyme's V max value, whereas it caused an approximately 10-fold increase Table 1 Primers used for site-directed mutagenesis
Primer name
Mutagenic primers (listed 5P to 3P, nucleotide change is underlined) Nucleotide position
a KH44A/AS and KH44A/S are the antisense and sense primers, respectively, used for the construction of the KH44A E1 mutant insert.
in the K m value for TPP. The mutant proteins had similar K m values for pyruvate as the wild-type E1 ( Table 2 ). The activities of the E1 mutant proteins in DCPIP assays were also reduced to the residual activity of 17% (KH44R), 43% (KH44Q) and 71% (KH44A) ( Table 2 ).
Phosphorylation and dephosphorylation of KH44R E1
In order to investigate whether the phosphorylation state of E1 in the patient with the KH44R mutation was contributing to his E1-de¢ciency, the rates of phosphorylation and dephosphorylation were measured. The rates of phosphorylation of wild-type and KH44R E1 sites 1 and 2 by rat PDK2 were found to be similar for these two proteins (results not shown). Additionally, after phosphorylation of sites 1 and 2 by rat PDK2 and ATP, the rates of phosphorylation of site 3 by rat PDK1 and [
32 P]ATP were measured for wild-type and KH44R E1 proteins and found to be similar (results not shown). The rates of dephosphorylation were also investigated using recombinant rat PDP1. The rates of dephosphorylation of sites 1 and 2 for wildtype and KH44R E1 proteins were measured after phosphorylation of these E1 proteins by PDK2. The rates of dephosphorylation of sites 1 and 2 were similar for wild-type and KH44R E1s. The rate of dephosphorylation of site 3 only was investigated using site 3-[ 32 P]phospho-E1 proteins. Again, the rates of dephosphorylation of wild-type and KH44R E1 proteins were similar for site 3 (results not shown). Therefore, the lack of E1 activity in KH44R E1 patients was not due to an increase in the ratio of phosphorylated (inactive)/dephosphorylated (active) E1.
Binding of E1 to the E2^E3BP subcomplex
It is postulated that the E1 heterotetramer binds to the E1-binding domain of the E2 component via its E1L subunit, as was shown for branched-chain Kketo acid dehydrogenase [32] . In order to elucidate whether any of these mutations cause a conformational change, which is interfering with the interaction of the E1 component with the E2 binding domain, the binding of the mutant and wild-type E1s to the E2^E3BP subcomplex was investigated. Titration The second experimental approach employed was to study direct binding of E1s with E2^E3BP using Fig. 3 . Stability of KH44R and KH44A E1s at 37³C in the presence and absence of the E2^E3BP subcomplex. (A) a, KH44R E1; R, KH44R E1 with 460 WM TPP; P, KH44R E1 with 1 mM TPP; 8, KH44R E1 in the presence of the E2^E3BP subcomplex. (B) a, KH44A E1; R, KH44A E1 with 46 WM TPP; P, KH44A E1 with 240 WM TPP; 8, KH44A E1 in the presence of the E2^E3BP subcomplex; E, KH44A E1 with 13 WM TPP in the presence of the E2^E3BP subcomplex; b, KH44A E1 with 65 WM TPP in the presence of the E2^E3BP subcomplex. Aliquots of E1 (1 Wg) incubated at 37³C for varying lengths of time were reconstituted to PDC and activity was measured in PDC reconstitution assay. gel-¢ltration. Fig. 2 shows the relative amount of the wild-type and mutant E1s bound to E2^E3BP (A) and unbound (B) after preincubation of E1s with E2^E3BP and separation by gel-¢ltration. As can be seen mutant E1s were bound to E2^E3BP in the same amounts as the wild-type E1 at three di¡erent ratios used. The calculated amount of E1 tetramers bound to the 60-mer of E2 was from 19 (at 100 Wg of E1/100 Wg of E2^E3BP) to 25 (at 200 Wg of E1/100 Wg of E2^E3BP).
As was expected, these results of both experimental approaches indicated that none of the mutations signi¢cantly a¡ect the ability of the mutant E1 proteins to bind to the E2^E3BP subcomplex.
Thermostability of E1 proteins at 37³C
The presence of TPP or E2^E3BP subcomplex in the incubation medium at 37³C did not have a bene¢cial e¡ect on the stability of wild-type E1 over the time course studied (results not shown). The KH44R E1 mutant alone was signi¢cantly less stable at 37³C than the wild-type E1 in the absence of E2^E3BP (Fig. 3A) . This mutant required a TPP concentration of 1 mM to stabilize it, similar to wild-type E1. However, in the presence of E2^E3BP, the stability of KH44R E1 was similar to the wild-type protein and it did not require the addition of any TPP (Fig. 3A) .
The KH44A E1 protein was signi¢cantly less stable at 37³C than the wild-type in the absence of the E2Ê 3BP subcomplex (Fig. 3B) . The e¡ect of varying concentration of TPP was investigated and a TPP concentration of 240 WM was needed in the incubation solution to stabilize KH44A E1 to wild-type E1 stability. In the presence of the E2^E3BP subcomplex, the KH44A E1 mutant required only 65 WM TPP in the incubation medium to be as stable as the wild-type E1 protein (Fig. 3B) .
KH44Q E1 mutant was much less stable than the wild-type E1 in the absence of the E2^E3BP subcomplex. With a concentration of 460 WM TPP in the incubation medium, the KH44Q E1 was as stable as the wild-type protein (Fig. 4A) . In the presence of the E2^E3BP subcomplex, it was still necessary to have 130 WM TPP to stabilize this protein similar to the wild-type (Fig. 4B ).
Discussion
In the past there have been several di¡erent approaches to elucidate the mechanism of particular amino acids in the structure^function of mammalian E1. The most common approaches are chemical modi¢cation of E1, expression of mutant E1 proteins in cells lacking endogenous E1, and biochemical analysis of recombinant mutant E1 proteins recreating the mutations identi¢ed in E1-de¢cient patients.
Chemical modi¢cation entails modifying E1 with speci¢c chemicals and investigating the a¡ects of these modi¢cations on E1 activity and its ability to bind pyruvate and TPP. Chemical modi¢cation of E1 has identi¢ed several residues in E1 important for catalysis: a lysine, a histidine, L-arginine-269, L-tryptophan-165 and K-cysteine-91. Stepp and Reed provided evidence that a lysine residue in the E1K subunit is involved in the binding of TPP using pyridoxal-5P-phosphate and NaCN [33] . Treatment of pigeon breast muscle E1 with diethylpyrocarbonate, which modi¢es histidine residues, inactivated PDC catalysis but did not a¡ect TPP or pyruvate binding [34] . This suggested that a histidine residue may be important not for the binding of substrates but for the second partial reaction, as PDC activity using HETPP as substrate was a¡ected by the modi¢cation [34] . The positions of these two residues, lysine and histidine, in the primary sequence are still not known. Using the sulfhydryl speci¢c reagent Nethylmaleimide (NEM), cysteine 91 in E1K was found to be catalytically important [35] . This was suggested because TPP plus pyruvate protected E1 from inactivation by NEM when preincubated with the enzyme [35] . N-bromosuccinimide was used to modify essential tryptophan residue of pigeon E1 and to identify critical tryptophan of bovine E1 as L-tryptophan-165 [36, 37] . Recently a study on the mutants of K-cysteine-91 and L-tryptophan-165 showed that both residues were involved in TPP binding and were important for stability of human E1 [38] . Arginine-269 of E1L subunit was identi¢ed as a critical amino acid residue protected by TPP and pyruvate from modi¢cation by pyreneglyoxal [39] .
A second method used to investigate the e¡ects of mutations in E1 on PDC activity is to express mutant E1 proteins in a E1K null gene cell line. This was done by Seyda et al. to quantify the e¡ects of mutations of four of the eight histidyl residues in mature E1K, namely H92, H113, H121, and H292 [40] . Mutation of histidine-92 or histidine-292 in E1K resulted in the inactivation of E1 [40] . Mutation of histidine-121 caused a decrease in the level of the K and L subunits in cell extracts, suggesting that this residue plays a role in assembly into mature E1 [40] . Histidine-113 mutation had only a marginal e¡ect on E1 activity [40] .
Lastly, nature has presented point mutations in patients that identify critical amino acids in E1. Patients with these point mutations display the symptoms of E1 de¢ciency: severe lactic acidosis, delayed neurological development, and often times early death. These mutant E1 proteins can then be recreated by site-directed mutagenesis, overexpressed as recombinant proteins, and their kinetic parameters measured. Several mutant E1 proteins found in patients, namely KM210V, KP217A and KR378H, have been characterized in this fashion [41] . K-Methionine-210, which is located in the putative TPP-binding motif, was found to play a role in TPP binding, while K-proline-217, also found in the TPP-binding motif, was found to be critical for structural integrity of the enzyme [41] . K-Arginine-378, which is found at the C-terminus, is critical for catalysis [41] . It was by this method that the biochemical basis for E1-de¢ciency in an KH44R E1 patient was investigated in the present study.
Histidine-44 is conserved in eukaryotic E1K sequences (e.g., human, rat, pig, yeast, and nematode) but not in prokaryotic E1K [42^46] . Mutation of histidine-44 to arginine was found in a boy who displayed elevated levels of lactate in the blood and cerebrospinal £uid (CBF) [18] . The patient had normal levels of E1K and E1L proteins in lymphoblastoid cells as measured by Western blotting using anti-E1 antibodies [18] . Naito et al. showed that increasing dietary thiamine caused a decrease in blood and CBF lactate levels. The recombinant KH44R E1 protein (patient's mutation) was not signi¢cantly di¡er-ent from the wild-type E1 in any of the following parameters tested: stability at 37³C in the presence of the E2^E3BP subcomplex, ability to bind to the E2^E3BP subcomplex, its ability to be phosphorylated at sites 1 and 2 by PDK2 or site 3 by PDK1, and its ability to be dephosphorylated at all three sites by PDP1.
E1 catalyzes two partial reactions, which can be investigated individually by comparing the E1 activities from DCPIP and PDC reconstitution assays. Whereas PDC reconstitution assay measures the rate-limiting step of PDC, reductive acetylation of lipoyl groups of E2, DCPIP assay measures the decarboxylation of pyruvate and the oxidation of acetyl moiety to acetate with concomitant reduction of DCPIP. Since the reduction in activity of KH44R E1 in DCPIP assay was as severe as in PDC reconstitution assay compared to wild-type E1, it suggests that mutation of K-histidine-44 is most likely interfering with the ¢rst partial E1 reaction, i.e., TPP-dependent decarboxylation of pyruvate.
Interestingly, the H44R, H44Q, and H44A mutations a¡ected V max and K m for TPP in an inverse relationship. Whereas H44R E1 (patient's mutation) only increased K m for TPP 3-fold, its V max was only V5% of the wild-type E1. H44Q E1 had a moderate increase in K m for TPP (7-fold) but was more active than the H44R E1 (V30% of wild-type). In contrast, the H44A E1 protein displayed wild-type E1 activity but had a markedly increase K m for TPP (V10-fold). As the side chain of the mutated residue at position 44 is reduced in size (e.g., from arginine to glutamine to alanine), an increase in the V max of the mutant protein is observed and also an increase in the K m for TPP. This suggests that the size of the side chain at this location is important for both catalysis and TPP binding. Since the histidine side chain is not absolutely necessary for the wild-type level of activity and glutamine, whose side chain can mimic histidine's hydrogen bonding, does not rescue the reduction caused by mutating histidine-44, histidine-44 is most likely not directly involved in catalysis. It appears more likely that the size of the side chain has a certain space limit that once over, causes a local conformational change that disturbs the active site of the protein and thus causes a decrease in catalytic activity. Substitution of the histidine residue by any of the three residues studied here caused a marked increase in the K m value for TPP. This suggests that this residue is playing a role in the binding of TPP either by the volume, stacking interactions, or by charge interactions of the histidine ring with other residues. A reported bene¢cial e¡ect of thiamine therapy in this patient by Naito et al. is supported by a 3-fold change in the K m value for TPP observed in the present study [18] .
